Læknablaðið - 15.11.2000, Blaðsíða 42

FRÆÐIGREINAR / LYFJAFRÆÐI
r
34. Wallace JL. Selective COX-2 inhibitors: is the water becoming
muddy? TiPS 1999; 20:4-6.
35. Marnett LJ, Kalgutkar AS. Cyclogenase 2 inhibitors:
discovery, selectivity and the future. TiPS 1999; 20:465-9.
36. Shiff JS, Rigas B. Aspirin for cancer. Nature Medicine 1999; 5:
1348-9.
37. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh J,
et al. Inhibition og angiogenesis by nonsteroidal anti-
inflammatory drugs: insight into mechanisms and implic-
ations for cancer growth and ulcer healing. Nature Medicine
1999; 5: 1418-23.
38. In't Veld BA, Ruitenberg A, Launer LJ, Hofman A, Breteler
MMB, Stricker BHC. Duration of non-steroidal anti-
inflammatory drug use and risk of Alzheimer's disease. The
Rotterdam study. World Alzheimer Congress 2000. Abstracts
On Disc (nr.^S). Washington DC, 8.-13.7. 2000.
39. Aisen PS. Effect of prednisone treatment in AD. The sixth
Stockholm/Springfield Symposium on Alzheimer's Disease.
Stockholm, 4.-7.4. 2000.
40. Sérlyfjaskrá 2000. Fréttabréf lyfjanefndar ríkisins 2000; 4 (1):
20-1.
41. Information frán Lákemedelsverket 2000; 11: 85.
42. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-
2, and COX-3 and the future treatment of chronic
inflammatory disease. Lancet 2000; 355: 646-8.
43. Willoughby DA, Moore AR, Colville-Nash PR.
Cyclopentenone prostaglandins - new allies in the war on
inflammation. Nature Medicine 2000; 6:137-8.
44. ISIS-2 (Second International Study of Infarct Survival).
Collaborative Group. Randomised trial of intravenous strep-
tokinase, oral aspirin, both or neither among 17 187 cases of
suspected acute myocardial infarction: ISIS-2. Lancet 1988; 13
ágúst: 349-60.
45. Steering Committee of the Physicians' Health Study Research
Group. Final report of the aspirin component of the ongoing
physisicians' health study. N Engl J Med 1989,321:129-35.
46. Manson JAE, Stampfer MJ, Graham A, Colditz MB, Walter C,
Willett MD, et al. A prospective study of aspirin use and
primary prevention of cardiovascular disease in women.
JAMA 1991; 266: 521-7.
47. Patrono C. Aspirin and human platelets: from clinical trials to
acetylation of cyclooxygenase and back. TiPS 1989; 10:453-8.
48. Willard JE, Lange RA, Hillis LD. The use of aspirin in
ischaemic heart disease. N Engl J Med 1992; 327:175-81.
49. Meade TW, Brennan PJ. Determination of who may derive
most benefit from aspirin in primary prevention: subgroup
results from a randomised controlled trial. BMJ 2000; 321:13-
7.
50. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu
LS, et al. Indications for early aspirin use in acute ischemic
stroke. A combined analysis of 40 000 randomized patients
from the Chinese acute stroke trial and the international
stroke trial. Stroke 2000; 31:1240-9.
51. Oberle S, Polte T, Abate A, Podhaisky H-P, Schröder H.
Aspirin increases ferritin synthesis in endothelial cells. A
novel antioxidant pathway. Circ Res 1998; 82:1016-20.
52. Collier HOJ, Schneider C. Nociceptive response to
prostaglandins and analgesic actions of aspirin and morphine.
Nature New Biology 1972; 236:141-3.
53. Ferreira SH. Prostaglandin, aspirin-like drugs and analgesia.
Nature New Biology 1972; 240: 200-3.
54. Ferreira SH, Lorenzetti BB, Corréa MA. Central and
peripheral antianalgesic action of aspirin-Iike drugs. Eur J
Pharmacol 1978; 53: 39-48.
55. McCormack K. Non-steroidal anti-inflammatory drugs and
spinal nociceptive processing. Pain 1994; 59: 9-43.
56. Malmberg AB, Yaksh TL. Pharmacology of the spinal action
of ketorolac, morphine, ST-91, U50488H, and L-PIA on the
formalin test and an isobolographic analysis of the NSAID
interaction. Anesthiology 1993; 79: 270-81.
57. Hunskaar S. Similar effects of acetylsalicylic acid and
morphine on immediate response to acute noxious
stimulation. Pharmacol Toxicol 1987; 60:167-70.
58. Stein C, Hassan AHS, Lehrberger K, Giefing J, Yassouridis A.
Local analgesic effect of endogenous opioidpeptides. Lancet
1993; 342: 321-4.
59. Herrero JF, Headley PM. Reversal by naloxone of the spinal
antinociceptive actions of a systemically-administered
NSAID. Br J Pharmacol 1996; 118: 968-72.
60. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG,
Schoenen J, Chazot G. The effectiveness of combined oral
lysine acetylsalicylate and metoclopromide compared with
oral sumatriptan for migraine. Lancet 1995; 346: 923-6.
61. Information frán Lákemedelsverket 1999; 10: 53-6.
62. Piomelli D, Giuffrida A, Calignano A, deFonseca FR. The
endocannabinoid system as a target for therapeutic drugs.
TiPS 2000; 21: 218-24.
63. Zygmunt PM, Julius D, Di Marzo V, Högestátt ED.
Anandamide - the other side of the coin. TiPS 2000; 21: 43-4.
64. Jóhannesson Þ. Sýklalyfjafræði I. 2. útg. Reykjavfk:
Háskólaútgáfan; 1995: 2-3,84-7.
65. Huang W-T, Lin M-T, Won S-J. Mechanisms and sites of
pyrogenic action exerted by staphylococcal enterotoxin A in
rabbits. Neuroscience Letters 1997; 236: 53-6.
66. Straub RH, Mánnel DN. How the immune system puts the
brain to sleep. Nature Medicine 1999; 5: 877-9.
67. Kramer MS, Naimark LE, Roberts-Bráuer R, McDougall A,
Leduc DC. Risks and benefits of paracetamol antipyresis in
young children with fever of presumed viral origin. Lancet
1996; 337: 591-4.
68. Mitchell JA, Saunders M, Barnes PJ, Newton R, Belvisi MG.
Sodium salicylate inhibits cyclooxygenase-2 activity independ-
ently of transcription factor (nuclear factor kB) activation:
role of arachidonic acid. Mol Pharmacol 1997; 51: 907-12.
69. Santucci L, Fiorucci S, Giansanti M, Brunori PM, DiMatteo
FM, Morelli A. Pentoxifylline prevents indomethacin induced
acute gastric mucosal damage in rats: role of tumor necrosis
factor alpha. Gut 1994; 35: 909-15.
70. Appleyard CB, McCafferty D-M, Tigley AW, Swain MG,
Wallace JL. Tumor necrosis factor mediation of NSAID-
induced gastric damage: role of leucocyte adherance. Am J
Physiol 1996; 270: G42-G48.
71. Badger AM, Lee JC. Advances in antiarthritic therapeutics.
Drug Discovery Today 1997; 10: 427-35.
72. Morgan GP, Williams JG. Inflammatory mediators in the
oesophagus. Gut 1994; 35: 297-8.
73. Möller AD. Low-dose prostacyklin. Physiological and
pathophysiological implications of its effects on microvascular
fluid permeability and perfusion [doctoral dissertation]. Lund:
Lund University; 1999.
74. Cronstein BN, Weissmann G. Targets for antiinflammatory
drugs. Annu Rev Pharmacol Toxicol 1995; 35: 449-62.
75. González-Alvaro I, Munoz C, García-Vicuna R, Sabando P,
Cabanas C, Sánchez-Madrid F, et al. Interference of non-
steroidal antiinflammatory drugs with very Iate activation
antigen 4/vascular cells adhesion molecule 1-mediated
lymphocyte-endothelial cell adhesion. Arthritis Rheum 1998;
41: 1677-90.
76. Salvemini D, Zhi-Qiang W, Zweier JL, Samouilov A,
MacArthur H, Misko TP, et al. A nonpeptidyl mimic of
superoxide dismutase with therapeutic activity in rats. Science
1999; 286:304-6.
77. Choy EHS, Scott DL. Drug treatment of rheumatic diseases.
Achievements and future developments. Drugs 1997; 53: 337-
48.
78. Fernandes JC, Martel-Pelletier J, Jovanovic D, Tardif G,
DiBattista JA, Laslau-Coman V, et al. The effects of tenidap
on canine experimental osteoarthritis: II. Study of the
expression of collagenase-1 and interleukin 16 by in situ
hybridization. J Rheumatol 1998; 25: 951-8.
79. Information frán Lákemedelsverket 2000; 11: 31-4.
80. Yin M-J, Yamamoto Y, Gaynor RB. The anti-inflammatory
agents aspirin and salicylate inhibit the activity of IkB kinase-
p. Nature 1998; 396: 77-80.
Mistök við prentun
I síðasta tölublaði Læknablaðsins 10/2000 urðu þau mistök við prentun að inn í grein Ásbjörns
Jónssonar Stafræn tækni opnar nýjar víddir í röntgenþjónustu (Læknablaðið 2000; 86: 677-81) slæddist
klausa sem birst hafði í næsta tölublaði þar á undan og átti að sjálfsögðu ekkert erindi inn í greinina.
Höfundur og lesendur eru beðnir afsökunar á þessum mistökum.
Við tilvísun í greinina skal leiðréttingar getið: Leiðrétting birt: Læknablaðið 2000; 86: 768.
768 Læknablaðið 2000/86